Writing in a viewpoint in JAMA, Walid F. Gellad, MD, MPH, and Chester B. Good, MD, MPH, both of the University of Pittsburgh, argue that the deep cost savings achieved in Europe for biosimilar adalimumab are unavailable to the United States because of settlements struck between AbbVie and the developers of all FDA-approved biosimilars.
In a climate of growing scrutiny of potential “pay-for-delay” patent litigation settlements, as well as antitrust lawsuits related to settlements concerning AbbVie’s blockbuster Humira, drug makers have been pushing back against suggestions that settlements made between biosimilar developers and AbbVie are harming competition in the United States.
For example, the Biosimilars Council, a part of the Association for Accessible Medicines, wrote in a white paper in June that these settlements with AbbVie—none of which will allow a biosimilar adalimumab to reach the US market before 2023—are pro-competitive in nature because they will allow biosimilars of the blockbuster therapy to reach US patients 11 years earlier than would otherwise be possible.
But not all stakeholders agree with that perspective, and this week, writing in a viewpoint in JAMA, Walid F. Gellad, MD, MPH, and Chester B. Good, MD, MPH, both of the University of Pittsburgh, argue that the deep cost savings achieved in Europe for biosimilar adalimumab are unavailable to the United States because of those very settlements struck between AbbVie and the developers of all FDA-approved biosimilars.1
By the time biosimilar adalimumab can launch in the US market, Gellad and Good write, orally administered treatments—even oral biologics—could plausibly have overtaken Humira in terms of market share, muting the effect of biosimilar entry.
If patients with inflammatory disease who currently take Humira are able to transition to more convenient options (like AbbVie’s small-molecule drug, upadacitinib) or more effective treatment options (like AbbVie’s risankizumab), they may not want to switch back to injectable adalimumab, despite the potential for reduced cost with biosimilars.
The authors predict that AbbVie will incentivize switching to its new, patent-protected agents “long before” biosimilar adalimumab becomes available, helping to ensure the company’s continued hold on the market for inflammatory diseases. They even suggest that an orally administered version of adalimumab may not be far off, which would further incentivize patients to remain on an AbbVie product rather than transition to a biosimilar.
All of these factors raise the question, say Gellad and Good, of whether the window for biosimilars to make an impact in the US market is closing.
“The example of adalimumab, including its biosimilar delay, injectable competitors, and now oral biologic competitors, should be a warning that speed is of the essence for establishing a robust biosimilar market in the United States,” they write.
Reference
1. Gellad WF, Good CB. Adalimumab and the challenges for biosimilars [published online October 23, 2019]. JAMA. doi: 10.1001/jama.2019.16275.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.